RxDoctor Payments Data

Krystine Swannick-Konopczynski, MD

Nephrology · Naples, FLNPI 1518989037

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 123 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$380
  • Vifor Pharma, Inc.$265
  • Otsuka America Pharmaceutical, Inc.$241
  • Bayer$202
  • Amgen$201
  • Amarin Pharma, Inc.$180
  • plus $457 from 9 others

What the payments were for

  • Food & beverage$1,85396%
  • Education$744%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,928 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$194,135
Medicare patients
442
Services billed
1,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol72$92,527
OzempicSemaglutide59$76,777
RayaldeeCalcifediol22$70,097
EliquisApixaban38$43,889
LokelmaSodium Zirconium Cyclosilicate43$42,040
JardianceEmpagliflozin37$41,952
MounjaroTirzepatide24$32,538
KerendiaFinerenone17$26,355
XareltoRivaroxaban13$20,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,309
VascepaIcosapent Ethyl18$15,886
Repatha SyringeEvolocumab16$12,586
Lagevrio (Eua)Molnupiravir13$4,849
Potassium Citrate ErPotassium Citrate26$3,442
Rosuvastatin Calcium210$3,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$380$134,567115 claims
Novo NordiskOzempic$64$76,77759 claims
OPKO Pharmaceuticals, LLCRayaldee$144$70,09722 claims
Lilly USA, LLCMounjaro$18$32,53824 claims
BayerKerendia$202$26,35517 claims
Johnson & JohnsonXarelto$28$20,93213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →